David A. Proia

4.3k citations

57 papers · 2.6k indexed · h-index 30

Oncology top 5%
Molecular Biology top 5%
- Heat shock proteins research 37
- ATP Synthase and ATPases Research 12
- Cancer therapeutics and mechanisms 5
- Ubiquitin and proteasome pathways 5
Cancer Research top 5%
Aging top 10%
Cell Biology top 5%
- Endoplasmic Reticulum Stress and Disease 5
Computational Theory and Mathematics
- Computational Drug Discovery Methods 7
Immunology
- Toxin Mechanisms and Immunotoxins 5
Radiology, Nuclear Medicine and Imaging
- Effects of Radiation Exposure 5

Co-authors: Richard C. Bates Charlotte Kuperwasser Jim Sang Suqin He Donald L. Smith Manuel Sequeira Chaohua Zhang Jaime Acquaviva
Cited by: Oncology Molecular Biology Cancer Research
Journals: Clinical Cancer Research (6 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (5 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

David A. Proia

57 papers receiving 2.6k citations

Peers

Countries citing papers authored by David A. Proia

Since Specialization

Citations

This map shows the geographic impact of David A. Proia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Proia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Proia more than expected).

Fields of papers citing papers by David A. Proia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Proia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Proia. The network helps show where David A. Proia may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David A. Proia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Proia Line = papers co-authored together David A. Proia links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents Hematological Oncology ·Michael J. Thomenius,Fuat Belli,Jason K. Kirby,Roman V. Agafonov,Prasoon Chaturvedi,Scott J. Eron,A. C. Good,John Hart,Miaoling He,Andrew J. K. Phillips,David A. Proia,James A. Henderson,Christopher G. Nasveschuk,Stewart L. Fisher,Roy M. Pollock	2023	4
2	A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination SLAS DISCOVERY ·S. Shikha,Roman V. Agafonov,Lydia M. Emerson,Marta Isasa,Richard W. Deibler,Jeffrey R. Simard,Temur Xudayberganov,Brendon Ladd,Linda Lee,Hui-Xin Dong,Stephen L. Archer,Mark E. Fitzgerald,Donald William Neale,Christopher G. Nasveschuk,Chang-Yeol Yim,Günther Kern,David A. Proia,Andrew J. Phillips,Stewart L. Fisher	2021	9
3	Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors Clinical Cancer Research ·Cheryl A. London,Jaime Acquaviva,Donald L. Smith,Manuel Sequeira,Luisa Shin Ogawa,Heather L. Gardner,G. Camoin,Misty D. Bear,Sandra M. Axiak‐Bechtel,David A. Proia	2018	8
4	Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation Clinical Cancer Research ·Yifan Wang,Hui Liu,Lixia Diao,Aderibigbe S. Olomola,Jianhu Zhang,Yawei Qiao,Jing Wang,David A. Proia,Ramesh Tailor,Ritsuko Komaki,Steven H. Lin	2016	27
5	A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer Clinical Cancer Research ·凌访贤,Anna S. Nikonova,Alexander Y. Deneka,Meghan C. Kopp,Alexander E. Kudinov,Nevita Feinbrianti,Vladimir Khazak,Luisa Shin Ogawa,Kathy Q. Cai,Kelly Duncan,James S. Duncan,Brian L. Egleston,David A. Proia,Yanis Boumber,Erica A. Golemis	2016	25
6	HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors Molecular Cancer Therapeutics ·David A. Proia,Donald L. Smith,Junyi Zhang,John-Paul Jimenez,Jim Sang,Luisa Shin Ogawa,Manuel Sequeira,Jaime Acquaviva,Suqin He,Chaohua Zhang,Vladimir Khazak,Igor Astsaturov,Takayo Inoue,Noriaki Tatsuta,Sami Osman,Richard C. Bates,Dinesh Chimmanamada,Weiwen Ying	2015	29
7	Resistance to HSP90 inhibition involving loss of MCL1 addiction Oncogene ·Sara Busacca,Hironobu Mita,Ian Powley,David A. Proia,Manuel Sequeira,John Le Quesne,Astero Klabatsa,Jennifer M. Edwards,Kyle B. Matchett,Jinli Luo,James H. Pringle,Mohamed El‐Tanani,Marion MacFarlane,Dean A. Fennell	2015	24
8	FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism Molecular Cancer Research ·Jaime Acquaviva,Suqin He,Chaohua Zhang,John-Paul Jimenez,Masazumi Nagai,Jim Sang,Manuel Sequeira,Donald L. Smith,Luisa Shin Ogawa,Takayo Inoue,Noriaki Tatsuta,Margaret A. Knowles,Richard C. Bates,David A. Proia	2014	57
9	mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis Molecular Cancer Research ·Jaime Acquaviva,Suqin He,Jim Sang,Donald L. Smith,Manuel Sequeira,Chaohua Zhang,Richard C. Bates,David A. Proia	2014	40
10	Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib Molecular Cancer Therapeutics ·Jaime Acquaviva,Donald L. Smith,John-Paul Jimenez,Chaohua Zhang,Manuel Sequeira,Suqin He,Jim Sang,Richard C. Bates,David A. Proia	2014	79
11	UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib Cell Death and Disease ·В. Ю. Гудыма,David A. Proia,India Claflin,Luisa Shin Ogawa,Frank Krämer,Tim Beißbarth,Marian Grade,Jochen Gaedcke,Michael Ghadimi,Ute M. Moll,Matthias Dobbelstein	2014	32
12	Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease Proceedings of the National Academy of Sciences ·Tamina Seeger‐Nukpezah,David A. Proia,Brian L. Egleston,Anna S. Nikonova,Tatiana Kent,Kathy Q. Cai,Harvey H. Hensley,Weiwen Ying,Dinesh Chimmanamada,Ilya G. Serebriiskii,Erica A. Golemis	2013	37
13	Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer Clinical Cancer Research ·Hanqing Liu,Erika Paola Vanegas Romero,Ilya G. Serebriiskii,Shane W. O’Brien,Tammy Doolittle,Igor Astsaturov,Samuel Litwin,Lainie P. Martin,David A. Proia,Erica A. Golemis,Denise C. Connolly	2013	41
14	Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer Clinical Cancer Research ·David A. Proia,Chaohua Zhang,Manuel Sequeira,John-Paul Jimenez,Suqin He,Neil L. Spector,Geoffrey I. Shapiro,Sara M. Tolaney,Masazumi Nagai,Jaime Acquaviva,Donald L. Smith,Jim Sang,Richard C. Bates,Iman El‐Hariry	2013	53
15	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Cancer Discovery ·Jim Sang,Jaime Acquaviva,Julie C. Friedland,Donald L. Smith,Manuel Sequeira,Chaohua Zhang,Qin Jiang,Liquan Xue,Christine M. Lovly,Laura Aillaud,Alice T. Shaw,Robert C. Doebele,Suqin He,Richard C. Bates,D. Ross Camidge,Stephan W. Morris,Iman El‐Hariry,David A. Proia	2013	174
16	Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3 Angiogenesis ·Ganji Purnachandra Nagaraju,Wungki Park,Jing Wen,Hemchandra Mahaseth,Jerome C. Landry,Alton B. Farris,Field F. Willingham,Patrick S. Sullivan,David A. Proia,Iman El‐Hariry,LaTonia Taliaferro‐Smith,Roberto Efraín Díaz,Bassel F. El‐Rayes	2013	71
17	Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib Molecular Cancer Therapeutics ·Jaime Acquaviva,Donald L. Smith,Jim Sang,Julie C. Friedland,Suqin He,Manuel Sequeira,Chaohua Zhang,Yumiko Wada,David A. Proia	2012	83
18	Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy Molecular Cancer Therapeutics ·Weiwen Ying,Zhenjian Du,Lijun Sun,Kevin P. Foley,David A. Proia,Ronald K. Blackman,Dan Zhou,Takayo Inoue,Noriaki Tatsuta,Jim Sang,Shuxia Ye,E. Alvarez,Luisa Shin Ogawa,Yumiko Wada,James Barsoum,Keizo Koya	2011	181
19	Systemic Stromal Effects of Estrogen Promote the Growth of Estrogen Receptor–Negative Cancers Cancer Research ·Piyush B. Gupta,David A. Proia,Oya Cingöz,MARIA VERÔNICA SALES DA SILVA,Stephen P. Naber,Robert A. Weinberg,Charlotte Kuperwasser	2007	138
20	Stroma: Tumor Agonist or Antagonist Cell Cycle ·David A. Proia,Charlotte Kuperwasser	2005	38

About David A. Proia

David A. Proia is a scholar working on Aging, Molecular Biology and Computational Theory and Mathematics, having authored 57 papers that have together received 2.6k indexed citations. Recurring topics across this work include Heat shock proteins research (37 papers), ATP Synthase and ATPases Research (12 papers), Computational Drug Discovery Methods (7 papers), Toxin Mechanisms and Immunotoxins (5 papers), Cancer therapeutics and mechanisms (5 papers), Ubiquitin and proteasome pathways (5 papers), Effects of Radiation Exposure (5 papers) and Endoplasmic Reticulum Stress and Disease (5 papers). The work is most often cited by research in Oncology (945 citations), Molecular Biology (1.9k citations) and Cancer Research (362 citations). David A. Proia has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Richard C. Bates, Charlotte Kuperwasser, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Jaime Acquaviva, Yumiko Wada and Ute M. Moll. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Molecular Cancer Therapeutics, Oncotarget and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact